Sign In To Continue
You have reached the guest article limit.
Unlock more of the IIPLA newsroom by signing in with SSO or joining as a member.
Akebia Therapeutics has been granted a new patent and qualified for a five-year patent term extension on its composition of matter patent for Vafseo® (vadadustat). This development strengthens the company’s intellectual property portfolio and extends market exclusivity for Vafseo®—an oral treatment for anemia due to c…
Share This Article
Ready-to-post copy includes the article link.
Akebia Therapeutics Secures New Patent and Five-Year Extension for Vafseo® (vadadustat), Bolstering Market Exclusivity Through 2036 Akebia Therapeutics has been granted a new patent and qualified for a five-year patent term extension on its composition of matter patent for Vafseo® (vadadustat). This development strengthens the company’s intellectual... Read the full IIPLA article: https://iipla.org/news/akebia-therapeutics-secures-new-patent-and-five-year-extension-for-vafseo-vadadustat-bolstering-market-exclusivity-through-2036